With short-term Treasury yields above 4% and longer-term government bonds offering more than 5%, investors have an unusual opportunity to earn meaningful income without taking corporate credit risk. But the difference between a three-month Treasury ETF and a long-term bond fund could determine whether investors preserve their capital or suffer substantial losses. There is something particularly appealing about earning 5% on an investment backed by the United States government. No quarterly earnings calls to worry about, no disappointing product launches, no executives explaining why spending another $40 billion on artificial intelligence will somehow become profitable eventually. Just government securities paying interest while investors get on with their lives. Unfortunately, Wall Street has a remarkable talent for making even relatively straightforward investments more complicated than they initially appear. Consider the Treasury market as of November 3, 2026. According to the U.S. D...
AbbVie Just Raised Its Dividend Again: Is This 2.52% Yield Worth Buying, or Has the Market Already Priced In the Good News?
AbbVie has increased its dividend by 5.2%, raised its earnings outlook, and delivered impressive growth from its two leading immunology drugs. But with shares trading near $289, substantial debt on the balance sheet, and an expensive acquisition strategy, dividend investors need to look beyond the latest payout increase. There is something reassuring about a company that keeps increasing its dividend. While Wall Street spends its days obsessing over artificial intelligence, economic forecasts, and whatever financial catastrophe happens to be fashionable this week, dividend investors tend to appreciate something considerably less complicated: a business that earns money and shares a portion of it with its owners. Unfortunately, a growing dividend does not automatically make a stock a good investment. That brings me to AbbVie (NYSE: ABBV), one of the more interesting dividend-growth stories in the pharmaceutical industry. On October 30, 2026, AbbVie announced that it would increase its q...